KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study

J Glob Antimicrob Resist. 2019 Jun:17:109-111. doi: 10.1016/j.jgar.2018.11.014. Epub 2018 Nov 20.

Abstract

Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonisation is a major risk factor for developing systemic infection. Ceftazidime/avibactam (CAZ/AVI) may have a role as decolonisation therapy in special situations.

Methods: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection.

Results: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised.

Conclusion: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients.

Keywords: Carbapenemase-producing Klebsiella pneumoniae; Ceftazidime; Ceftazidime/avibactam; Gut decolonisation; KPC.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azabicyclo Compounds / therapeutic use*
  • Bacterial Proteins
  • Ceftazidime / therapeutic use*
  • Drug Combinations
  • Female
  • Gastrointestinal Tract / microbiology*
  • Humans
  • Klebsiella Infections / drug therapy*
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / enzymology
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Retrospective Studies
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Bacterial Proteins
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Ceftazidime
  • beta-Lactamases
  • carbapenemase